Adalimumab vs active comparators
Adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
12 questions · 12 findings · 4 reviews · Gut
No studies found 4 · 33.3%GRADE not reported 0 · 0%Very low 2 · 16.7%Low 2 · 16.7%Moderate 3 · 25%High 1 · 8.3%
Adalimumab vs placebo
Adverse events · Participants with Crohn's disease in remission
Adalimumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
- RR 1.01 [0.94, 1.09]4 studies · 1012 participantsHigh
Adalimumab vs active comparators
Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Adalimumab vs placebo
Serious adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.56 [0.39, 0.8]4 studies · 1012 participantsModerate
Adalimumab vs placebo
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
- Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Adalimumab vs active comparators
Withdrawals due to adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Adalimumab vs placebo
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.59 [0.38, 0.91]4 studies · 1012 participantsModerate
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
- RR 0.9 [0.74, 1.09]3 studies · 531 participantsModerate
Infliximab vs adalimumab
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
- Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes onlyRR 0.09 [0.01, 1.54]1 study · 73 participantsVery low
Intervention not reported
Serious adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
- RR 0.44 [0.17, 1.15]3 studies · 531 participantsLow
Infliximab vs adalimumab
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
- Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes onlyRR 0.1 [0.01, 0.72]1 study · 73 participantsVery low
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review
- RR 0.38 [0.11, 1.3]3 studies · 531 participantsLow